EA202092829A1 - Композиции тофацитиниба с контролируемым высвобождением - Google Patents

Композиции тофацитиниба с контролируемым высвобождением

Info

Publication number
EA202092829A1
EA202092829A1 EA202092829A EA202092829A EA202092829A1 EA 202092829 A1 EA202092829 A1 EA 202092829A1 EA 202092829 A EA202092829 A EA 202092829A EA 202092829 A EA202092829 A EA 202092829A EA 202092829 A1 EA202092829 A1 EA 202092829A1
Authority
EA
Eurasian Patent Office
Prior art keywords
topacitinib
compositions
controlled release
tablet
tofacitinib
Prior art date
Application number
EA202092829A
Other languages
English (en)
Inventor
Луис Ногейрас Ньето
Лисардо Альварес Фернандес
Рохит Кумар
Original Assignee
Синтон Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтон Б.В. filed Critical Синтон Б.В.
Publication of EA202092829A1 publication Critical patent/EA202092829A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Настоящее изобретение относится к композиции таблетка-в-таблетке для перорального введения тофацитиниба или его фармацевтически приемлемой соли.
EA202092829A 2018-05-24 2019-05-14 Композиции тофацитиниба с контролируемым высвобождением EA202092829A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18174120 2018-05-24
PCT/EP2019/062390 WO2019224058A1 (en) 2018-05-24 2019-05-14 Controlled release tofacitinib compositions

Publications (1)

Publication Number Publication Date
EA202092829A1 true EA202092829A1 (ru) 2021-05-20

Family

ID=62386025

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092829A EA202092829A1 (ru) 2018-05-24 2019-05-14 Композиции тофацитиниба с контролируемым высвобождением

Country Status (3)

Country Link
EP (1) EP3810096A1 (ru)
EA (1) EA202092829A1 (ru)
WO (1) WO2019224058A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111698983B (zh) 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
US11766438B2 (en) 2020-04-24 2023-09-26 Slayback Pharma Llc Pharmaceutical compositions of tofacitinib for oral administration
EP4259107A1 (en) * 2020-12-08 2023-10-18 Triastek, Inc. Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of use thereof
EP4347028A1 (en) * 2021-06-04 2024-04-10 Synthon B.V. Prolonged release tofacitinib compositions
WO2024042218A1 (en) * 2022-08-26 2024-02-29 Synthon B.V. Prolonged release tofacitinib compositions without functional coating

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
EP3810096A1 (en) 2021-04-28
WO2019224058A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EA201692298A1 (ru) Производные карбоксамидов
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.